Syndax shares slump 16% after axatilimab misses mid-stage trial goal
Syndax Pharmaceuticals said its experimental drug axatilimab missed the main goal of a mid-stage study in idiopathic pulmonary fibrosis. Shares fell 15% after hours on Monday.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.